Association of common genetic variation in the protein C pathway genes with clinical outcomes in acute respiratory distress syndrome

Table 1 Characteristics of patients from the Fluid and Catheter Treatment Trial

Variable	Caucasians with DNA (n = 320)	Caucasians without DNA (n = 321)	p Value
Age, years, mean ± SD	50 ± 16	52 ± 16	0.06
Male sex, %	51 %	51 %	0.96
APACHE III score, mean ± SD	92 ± 29	92 ± 31	0.77
Clinical disorders associated with acute lung injury
Pneumonia, %	46 %	47 %	0.78
Trauma, %	8 %	5 %	0.15
Sepsis, %	21 %	25 %	0.26
Multiple transfusions, %	2 %	1 %	0.25
Aspiration, %	17 %	17 %	0.90
Baseline PaO₂/FiO₂	103 ± 48	106 ± 49	0.45
Severity of ARDS			0.36
Mild	59 %	53 %
Moderate	36 %	41 %
Severe	5 %	6 %
Day 1 PIP	32 ± 8	32 ± 9	0.32
Day 1 PEEP	9.4 ± 4	9.5 ± 4	0.7
Fluid management, liberal, %	48 %	55 %	0.09
Mortality at 60 days, %	21 %	25 %	0.19
Ventilator-free days, median (range)	19 (0–28)	17 (0–28)	0.22

APACHE Acute Physiology and Chronic Health Evaluation, ARDS acute respiratory distress syndrome, FiO ₂ fraction of inspired oxygen, PaO ₂ partial pressure of arterial oxygen, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure